PAPP-A: a promising therapeutic target for healthy longevity

Area of Science:

• Biochemistry and Molecular Biology
• Aging Research
• Endocrinology

Background:

• Pregnancy-associated plasma protein-A (PAPP-A) is an enzyme that enhances insulin-like growth factor (IGF) signaling by cleaving IGF binding proteins (IGFBPs).
• Reduced IGF signaling is linked to increased lifespan and healthspan in various organisms.
• PAPP-A plays a role in modulating IGF bioavailability and activity.

Purpose of the Study:

• To review evidence supporting PAPP-A as a therapeutic target for promoting healthy longevity.
• To explore the mechanism by which PAPP-A inhibition could impact IGF signaling.
• To discuss the potential of targeting PAPP-A for age-related health improvements.

Main Methods:

• Literature review of studies on PAPP-A function and IGF signaling.
• Analysis of data linking IGF pathway modulation to longevity.
• Examination of PAPP-A's role in physiological processes relevant to aging.

Main Results:

• PAPP-A activity increases local IGF availability, promoting growth and cellular processes.
• Inhibiting PAPP-A can decrease IGF signaling, which is associated with extended healthspan.
• Data suggests a conserved role for IGF signaling in aging and lifespan regulation.

Conclusions:

• Inhibition of PAPP-A offers a novel strategy to modulate IGF signaling.
• Targeting PAPP-A may represent a therapeutic approach to promote healthy aging and longevity.
• Further research into PAPP-A inhibitors could yield significant benefits for healthspan extension.